Aug. 20 at 6:05 PM
$XERS
Summary
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of
$203M, up 24%, with robust growth across all three commercial products.
2025 revenue guidance of
$255M–
$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation.
XP-8121, a once-weekly injectable levothyroxine, targets a
$1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
New XERS CEO John Shannon emphasizes rapid commercial growth, financial discipline, and pipeline innovation, with Wall Street responding positively.
https://seekingalpha.com/article/4938835-xeris-biopharma-commercial-stage-pharma-may-be-slow-burn-buy-opportunity
